Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cholecystitis01:20

Cholecystitis

Cholecystitis is inflammation of the gallbladder, most commonly caused by obstruction of the cystic duct. This blockage prevents bile from draining, leading to gallbladder distension, inflammation, and potentially serious complications. This condition may present acutely or chronically and can happen with or without gallstones.EtiologyAbout 95% of cholecystitis cases are calculous, caused by gallstones blocking the cystic duct, leading to bile accumulation and inflammation of the gallbladder...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Gallbladder01:17

Gallbladder

The gallbladder is a small, pear-shaped organ that plays a crucial role in our digestive system. Measuring about 10 cm in length, it is comparable in size to a kiwi fruit and is located in a hollow area on the lower surface of the liver. The gallbladder's primary function is to store and concentrate bile, a fluid produced by the liver that aids in digestion.
The gallbladder's anatomy consists of three regions: the fundus, body, and neck. Extending from the neck, the cystic duct joins the common...
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
Gastritis II: Pathophysiology01:26

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
Gastritis-I: Introduction and Types01:27

Gastritis-I: Introduction and Types

Gastritis, defined by the inflammation or irritation of the stomach lining or gastric mucosa, manifests in several distinct forms: acute, chronic, reactive, and a specific subtype known as autoimmune metaplastic atrophic gastritis.
Acute gastritis presents as a sudden inflammation triggered by various stressors to the stomach lining, such as exposure to corrosive agents, local irritants like aspirin and other NSAIDs, alcohol consumption, radiation therapy, physical trauma, severe burns, sepsis,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Club Rhumatismes et Inflammation guidelines for anti-interleukin-1 therapy: 2026 update.

Joint bone spine·2026
Same author

Reliability of ultrasound assessment of elementary lesions in psoriatic arthritis and development of a reference dactylitis atlas.

Rheumatology (Oxford, England)·2026
Same author

Urate Lowering and Cardiovascular Risk-Extending the Benefits of a Treat-to-Target Strategy in Gout.

JAMA internal medicine·2026
Same author

Screening for transthyretin amyloid cardiomyopathy in patients with musculoskeletal symptoms: Red flags in the rheumatology/orthopedics practice setting.

Joint bone spine·2025
Same author

Transcutaneous auricular vagus nerve stimulation versus sham stimulation in patients with erosive hand osteoarthritis (ESTIVAL): a randomised, multicentre, double-blind, sham-controlled trial.

The Lancet. Rheumatology·2025
Same author

Photon-counting CT of Bone Erosions Induced by Gouty Tophi.

Radiology·2025
Same journal

Convergence of metabolic risk in obesity and normal BMI: does risk disappear?

Lancet (London, England)·2026
Same journal

Metabolic traits in obesity and normal BMI in industrialised countries: a multi-country analysis of national population-based studies.

Lancet (London, England)·2026
Same journal

Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective.

Lancet (London, England)·2026
Same journal

The US Ebola response and the future of global health leadership.

Lancet (London, England)·2026
Same journal

Daniel Mason: a tale of change.

Lancet (London, England)·2026
Same journal

The 2026 Wakley-Wu Lien Teh Prize Essay: why medicine, and why stay?

Lancet (London, England)·2026
See all related articles

Related Experiment Video

Updated: Jun 20, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

Gout.

Pascal Richette1, Thomas Bardin

  • 1Université Paris 7, UFR Médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, Paris, France. pascal.richette@lrb

Lancet (London, England)
|August 21, 2009
PubMed
Summary
This summary is machine-generated.

Gout, a common inflammatory arthritis from uric acid crystal buildup, affects 1-2% of adults. Lowering serum uric acid dissolves crystals, curing gout, alongside lifestyle changes and comorbidity management.

Related Experiment Videos

Last Updated: Jun 20, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

Area of Science:

  • Rheumatology
  • Metabolic Diseases
  • Crystal Arthropathies

Background:

  • Gout is a prevalent inflammatory arthritis caused by monosodium urate crystal deposition due to chronic hyperuricemia.
  • Affecting 1-2% of adults in developed nations, gout is the most common inflammatory arthritis in men, with rising prevalence.
  • Primary gout is linked to diet and genetic factors influencing renal urate transporters.

Purpose of the Study:

  • To review the epidemiology, causes, comorbidities, and management of gout.
  • To highlight current and potential therapeutic targets for gout management.
  • To emphasize the importance of patient education and comorbidity treatment.

Main Methods:

  • Literature review of epidemiological data on gout prevalence and risk factors.
  • Analysis of current pharmacological treatments for acute gout attacks.
  • Discussion of emerging therapeutic targets, including Interleukin-1beta.

Main Results:

  • Gout prevalence is increasing, associated with lifestyle and genetic factors.
  • Non-steroidal anti-inflammatory drugs and colchicine are standard acute treatments; oral corticosteroids are an alternative.
  • Lowering serum uric acid below saturation point can dissolve crystals and cure gout.

Conclusions:

  • Gout management requires addressing hyperuricemia, acute attacks, and associated comorbidities.
  • Therapeutic strategies include lifestyle modification, pharmacotherapy, and potentially targeting inflammatory mediators like Interleukin-1beta.
  • Achieving sustained reduction in serum uric acid is key to resolving gout and preventing crystal formation.